key: cord-1022241-llsjof71
authors: AlSamman, Marya; Caggiula, Amy; Ganguli, Sangrag; Misak, Monika; Ali Pourmand
title: Non-respiratory presentations of COVID-19, a clinical review
date: 2020-09-24
journal: Am J Emerg Med
DOI: 10.1016/j.ajem.2020.09.054
sha: 8f6dabe9be5d3af3ab67e501638a7cf27ff8e182
doc_id: 1022241
cord_uid: llsjof71

INTRODUCTION: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19) is a highly infectious viral syndrome currently threatening millions of people worldwide. It is widely recognized as a disease of the pulmonary system, presenting with fever, cough, and shortness of breath. However, a number of extrapulmonary manifestations have been described in the literature. OBJECTIVE: In this review, we seek to provide a comprehensive summary of the hematologic, gastroenterological, renal, dermatologic, neurologic, and psychiatric manifestations of COVID-19. DISCUSSION: Hematological presentations of COVID-19 include laboratory abnormalities such as decreased total lymphocyte count, prolonged prothrombin time (PT), elevated d-dimer, and increased lactate dehydrogenase (LDH). Several of these findings are associated with increased mortality among infected patients. The most common gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal pain. Furthermore, presence of viral RNA in patient stool suggests the possibility of additional testing modalities for COVID-19. Nephrological findings such as proteinuria, hematuria, and elevated BUN and creatinine levels have been observed. Additionally, several studies demonstrated that patients with COVID-19 who developed acute kidney injury (AKI) had a greater risk of mortality. The virus can also present with cutaneous symptoms such as erythematous rashes, urticaria, and chicken pox-like lesions. Neuropsychiatric symptoms have been described in the literature, and patients can exhibit findings consistent with viral encephalitis, cerebral vascular disease, peripheral nerve disorders, and psychosis. CONCLUSION: Although COVID-19 does usually present primarily with respiratory symptoms, the extra-pulmonary manifestations of the virus are unpredictable and varied. Better understanding and awareness of these symptoms can lead to more efficient diagnosis, rapid treatment, isolation, and decreased spread of the disease.

Several studies have shown that patients infected with COVID-19 share similar laboratory abnormalities including decreased total lymphocyte count, prolonged prothrombin time, elevated d-dimer levels and increased lactate dehydrogenase (LDH) 2-8 . A recent meta-analysis of the laboratory derangements in COVID-19 demonstrated that lymphopenia (35-75% of cases), increased LDH (27-92% of cases), elevated and d-dimer (36-43% of cases) were among the most frequent findings 9 .

Patients with significant lab derangements had more severe disease and a greater need for critical care 2, 3, 5, 6, [9] [10] [11] [12] . Lymphopenia is often more pronounced in those requiring ICU level care [11] [12] [13] [14] [15] . In Singapore, Fan et al. noted that 28% of patients infected with COVID-19 had lymphopenia, with critical care patients demonstrating significantly decreased lymphocytes compared with those not requiring ICU treatment 14 . Furthermore, 4 of the 9 ICU patients also exhibited increased levels of LDH (median value of 1684 U/L) compared to the non-ICU patients where only 5 of 26 had moderately elevated LDH 14 . Huang et al. demonstrated that in addition to marked lymphopenia, patients needing intensive care had higher levels of d-dimer (level 2.4 mg/L [0. 6-14.4 ]) on admission than those who did not require it (0.5 mg/L [0.3-0.8], p=0.0042) and also higher prothrombin times 12.2s ] when compared with non-ICU patients (10.7s [9.8-12 .1], p=0·012). 3 In a study of 140 COVID-19 positive patients by Zhang et al., 58 patients who were considered to have "severe disease" demonstrated a 2-fold increase in d-dimer compared to those with mild disease 16 . Guan et al. also determined that a significant elevation in ddimer was more pronounced in severe cases (59.6% vs. 43 .2% in non-severe) 5 .

A meta-analysis examining the role of laboratory abnormalities in patients with severe COVID-19 vs. those with milder disease determined that the most predictive parameters of critical infection were lymphopenia (96.1% vs. 80.4%), thrombocytopenia (57.7% vs. 31.6%), increased LDH (58.1% vs. 37.2%) and elevated d-dimer (59.6% vs. 43.2%). 9 Specifically, in Wu et al.'s retrospective analysis of the risk factors for disease progression to ARDS, they observed a statistically significant association between lymphopenia and the development of ARDS (P <0.001) 8 . Several studies also established that higher CRP levels correlated with worse outcomes in COVID-19 such as ARDS, myocardial injury, and death 8, 15, 17 . As such, tracking hematologic parameters is crucial in determining prognosis and management, particularly with regard to level of care and monitoring.

In addition to indicating the potential for more severe disease, laboratory abnormalities are also a predictor of mortality in infected patients 2, 13 . In a case series of 138 patients with COVID-19, the mortality rate was about 4.3% (6 patients). Of those 6, 5 patients had persistent lab derangements including increased d-dimer and decreased lymphocyte counts 2 . Another retrospective cohort showed that elevated d-dimer was associated with a higher rate of in-hospital death with 81% of terminal cases J o u r n a l P r e -p r o o f exhibiting d-dimer >1 mcg 13 . Tang et al. analyzed abnormal coagulation parameters in patients with SARS-CoV-2 pneumonia and determined that non-survivors had significantly higher d-dimer, fibrin degradation products (FDP), and prothrombin time on admission compared to survivors (P < .05) 18 . This study was further supported by Han et al. who also demonstrated that d-dimer and FDP were especially predictive of disease progression 19 . A recent report investigating the factors affecting 28-day mortality of patients with severe illness showed that elevated d-dimer, increased age, and prolonged PT were associated with a higher mortality 20 . Early recognition of these abnormal results will play a critical role in predicting disease severity and improving outcomes with earlier intervention and supportive therapy.

Coagulation parameters are often cited as indicators for worse prognosis in patients infected with COVID-19 17, 19, 21 . Compared to a healthy control, d-dimer, FDP, and fibrinogen levels are all increased in COVID-19 patients, while antithrombin (AT) levels are significantly reduced 19 . Emerging data suggests that deregulated thrombin generation and abnormal activation of the coagulation cascade can lead to the development of disseminated intravascular coagulation (DIC) and is associated with worsening pneumonia and mortality 7, [22] [23] [24] . DIC was a significantly more common finding in non-survivors (71.4%) vs. survivors (0.6%) 18 . Other manifestations of coagulopathy such as the development of antiphospholipid antibodies and subsequent thrombotic events were reported in 3 ICU patients infected with SARS-CoV-2 in Wuhan, China 25 . Due to coagulation abnormalities, COVID-19 patients are at a higher risk of VTE, especially those with pre-existing comorbidities 23 . Early monitoring of these parameters can help guide medical management such as the use of VTE prophylaxis and escalation of care.

A study of COVID-19 patients from the First Affiliated Hospital of Zhengshou University, Henan, China demonstrated that infected patients have an overall pro-thrombotic state due to platelet hyperactivity 26 . When SARS-CoV-2 and its spike protein bind directly to the platelet and ACE2 receptor, there is increased platelet activation and thrombus formation due to activation of the MAPK pathway. This facilitates the release of coagulation and inflammatory factors, leading to an overall pro-thrombotic and pro-inflammatory state 26 . The authors also suggest that the addition of ACE2 protein and anti-Spike neutralizing antibodies may be a therapeutic approach to avoid thrombotic events in these patients.

Patients with critical COVID-19 infection can also present with various cardiovascular symptoms. Animal models and cardiac autopsies suggest that COVID-19 can infect the cardiac tissue by binding to the angiotensin-converting enzyme (ACE) receptors, which can result in myocardial inflammation and damage 27 . Among the reported cardiac manifestations of COVID-19 are myocardial injury, myocarditis, arrythmias, cardiomyopathy, and heart failure. These symptoms are summarized in Table 1 .

Myocardial injury is defined as an elevation in biomarkers such as cardiac troponin I. Acute myocardial injury was reported in some of the earliest cases of COVID-19 in Wuhan, China. An early 2019 study among 41 admitted hospital patients in Wuhan reported acute cardiac injury in 12% of the patients 3 . Furthermore, another study of 138 hospitalized patients in Wuhan reported that as high as 22% of those who required ICU care experienced acute myocardial injury 2 . Another retrospective, observational study of 52 critically ill patients in Wuhan, China reported cardiac injury in 23% of the patients 28 . The increased prevalence of cardiac injury among patients with COVID-19 could be explained by the significantly higher levels of cardiac troponin I in severely ill patients 29 .

A recent multi-hospital retrospective cohort of nearly 3,000 patients demonstrated that myocardial injury was common among hospitalized COVID-19 patients (n=985, 36%), and that those with a history of cardiovascular disease (CVD) were more likely to experience myocardial injury than those without 30 . Similarly, A study of 44,672 patients with COVID-19 demonstrated that a history of CVD was associated with a five-fold increase in case fatality rate compared to those without CVD (10.5% VS. 2.3%) 31, 32 .

A study by Lala, et al., showed that mild myocardial injury as evidenced by small increases in troponin was significantly associated with death (adjusted hazard ratio: 1.75; 95% CI: 1.37 to 2.24; p < 0.001), and that greater elevations correlated with a higher risk of mortality (adjusted HR: 3.03; 95% CI: 2.42 to 3.80; p < 0.001) 30 . Similarly, a single center retrospective study of 50 COVID-19 ICU patients in Turkey demonstrated that cardiac biomarkers including troponin I and NT-proBNP were higher in non-survivors compared to survivors 33 .

Myocarditis has also contributed to mortality associated with COVID-19. In a case series of 150 patients, researchers determined that 7% died from myocarditis with circulatory failure 34 . Clinically, diagnosing myocarditis can be challenging, especially when differentiating it from acute coronary syndrome. For this reason, echocardiogram evaluation is recommended, and myocarditis associated with COVID-19 will appear as global wall motion dysfunction without focal wall motion defects 31, 35, 36 . Additionally, ECG abnormalities may occur as a result of myocardial inflammation, such as T wave inversion, PR and ST segment deviations 31 . Autopsy reports of COVID-19 patients have reported high viral loads, mononuclear cells, and lymphocytic infiltration as key players in mediating acute myocarditis 37,38,39 .

A wide variety of arrythmias have been observed in patients with COVID-19. In a study of 137 patients in Hubei Province, 7.3% of patients reported heart palpitations 40 . In another report of 138 hospitalized patients, cardiac arrythmia was noted in 16.7%, and these arrythmias were more common in ICU patients 2 . In a much larger study of 700 patients, 9 cardiac arrests, 25 atrial fibrillation events, 9 clinically significant bradyarrhythmias, and 10 non-sustained ventricular tachycardias were reported 41 . Additionally, this study noted that ICU admissions were associated with incidents of atrial fibrillation J o u r n a l P r e -p r o o f among COVID-19 patients, indicating that these arrythmias can contribute to severity of illness 41 . Lastly, a retrospective case series published in Cureus discussed COVID-19 related prolonged QTc and transient bradycardia as manifestations of the illness 42 .

Many etiologies have been proposed to explain the occurrence of arrythmias among COVID-19 patients. Hypoxia, inflammatory damage, abnormal metabolism, neurohormonal stress, and response to medications are some of the likely etiologies 31, 35, 42 . Furthermore, the effect of pro-inflammatory cytokines on the sinoatrial node could lead to the development of bradycardia in patients with COVID-19 42 .

In a retrospective cohort study of COVID-19 patients in Wuhan, China, Zhou et al. reported heart failure in 23% of admitted patients 13 . This number was as high as 52% in those who did not survive the infection 13 . Another retrospective study demonstrated that heart failure and acute cardiac injury were more common in deceased patients, regardless of their cardiovascular history 43 . Specifically, this study reported heart failure in 24% of deceased patients, nearly half of whom did not have any history of cardiovascular disease or hypertension 43 . It is unclear whether the heart failure was due to a new cardiomyopathy or an exacerbation of existing undiagnosed left ventricular dysfunction, and the etiology is still being investigated 31, 35 . Additionally, right heart failure can occur in patients with severe lung injury and ARDS 31, 35 . As such, physicians should be cautious of underlying cardiac dysfunction when administering IV fluids 31, 35 .

Several recent case reports have also highlighted the development of Takotsubo Syndrome (TTS) in those infected with COVID-19 [44] [45] [46] [47] . One report detailed the case of a patient who developed cardiogenic shock 16 days after infection despite normal initial troponin levels and LVEF 44 . Her bedside echo demonstrated the apical ballooning typical of TTS. Similarly, another case report discussed the case of a previously healthy 50 years old male who developed chest pain and signs of cardiogenic shock 8 days after the onset of symptoms. His echocardiogram showed akinesia of all of his basal segments, and he was ultimately diagnosed with inverted Takotsubo cardiomyopathy 45 .

While the most fatal complications of COVID-19 include ARDS, heart failure, renal failure, liver injury, and multiple organ dysfunction syndrome (MODS), GI symptoms can contribute significantly to morbidity in infected patients 48 . With regard to the gastrointestinal system, SARS-CoV-2 can present with nausea, vomiting, diarrhea, and/or abdominal discomfort 3,49-53 . A cross-sectional analysis of 204 Chinese patients with COVID-19 demonstrated that over half (103 patients, 50.5%) reported experiencing at least one of the GI symptoms. Among those, 78.6% expressed loss of appetite, 34% complained of diarrhea, 3.9% reported vomiting, and 1.9% indicated they had abdominal pain 54 . Similar clinical studies among COVID-19 patients have observed diarrhea in 3% to 61% of patients, nausea in 10% to 58%, and vomiting in 2% to 5%. Other gastrointestinal symptoms included epigastric pain, belching, and anorexia 16, [55] [56] [57] [58] (summarized in Table 2 ).

Healthcare workers can easily be overwhelmed by the complex symptomology and acuity of cases. While focusing primarily on the most critical respiratory symptoms, gastrointestinal manifestations can be overlooked. Though GI symptoms are not prominent in most cases and are unlikely life-threatening on their own, clinicians should endeavor to identify these early symptoms in order to prevent the potential spread of COVID-19.

Some studies have shown that GI symptoms can manifest before the onset of typical respiratory symptoms 2,59 . The first confirmed case of COVID-19 in the US presented with a two-day history of nausea without respiratory complaint. Days into the illness, the patient also complained of abdominal discomfort and loose stools 60 . Similarly, a recent report described a COVID-19 patient presenting with diarrhea, borborygmus, anorexia, and nausea in the absence of any respiratory symptoms 61 . Early research has suggested a correlation between GI symptoms and severity of illness. Henry et al. performed a pooled analysis of 10 different studies with a total sample of 1989 COVID-19 patients, 598 of whom (30.1%) were deemed as having "severe disease." This study examined whether patients presenting with GI symptoms could be at an increased risk of critical illness and poor prognosis. The research highlighted a significant association between abdominal pain and illness severity. Furthermore, nausea and vomiting correlated with a marginally increased risk of severe COVID-19, while diarrhea was not reported to be associated with worse disease 62 . Another retrospective case-controlled study of 278 COVID-19 positive patients and 238 COVID-19 negative patients suggested that patients presenting with GI symptoms at time of testing were more likely to test positive for the virus 63 . In comparison, patients without GI symptoms were equally likely to test positive or negative for COVID-19 63 . Lastly, in the past few months, two cases of paralytic ileus were reported among COVID-19 patients 64 . Histopathology of resected bowel specimen in these cases suggests a role for COVID-19-induced micro-thrombosis leading to GI perforation 64 .

In addition to research showing the potential correlation between GI symptoms and disease severity, several studies have determined that infected patients can shed viral particles in their stool [65] [66] [67] . One study of 42 COVID-19 positive patients demonstrated that about 67% of the patients had viral RNA present in their stool even in the absence of diarrhea or other GI symptoms. Interestingly, among this group, 64% of the patients continued to shed viral particles in fecal specimens even after the nasopharyngeal swabs turned negative 65 Fecal specimen testing is just as accurate in detecting COVID-19 as nasopharyngeal swabs 66, 69 . Physiologically, the presence of viral particles in feces is plausible as there is a high level of viral receptor angiotensin converting enzyme 2 (ACE2) in the gastrointestinal tract 70 . While the current research is not definitive, studies have indicated that asymptomatic patients may shed COVID-19 viral particles in their stool 66, [71] [72] [73] [74] . Whether these particles are infectious and support the argument for possible the fecal-oral transmission of SARS-CoV-2 remains unclear.

Several studies have examined whether GI procedures such as endoscopies can safely be performed on COVID-19 positive patients. A study conducted in northern Italy identified 23 COVID-19 patients presenting with signs of upper GI bleeding, therefore necessitating urgent endoscopy 75 . The virus has been detected in biopsies of the esophagus, stomach, duodenum, and rectum 76 . Since endoscopes are in contact with mucus membrane and body fluids, it is possible that these instruments can be implicated in transmission the virus 77 . As such, most guidelines recommend the use of personal protective equipment (PPE) during endoscopic examination in order to prevent nosocomial outbreaks of COVID-19 [78] [79] [80] [81] . When the virus is highly suspected or confirmed, double gloves and N95 or FFP2/3 masks are indicated and the operative team should be properly trained to wear and remove PPE safely 79 .

SARS-CoV-2 can have a profound impact on the renal system. Early research has determined that COVID-19 can directly infect kidney tubules and cause acute tubular damage and subsequent renal failure 82, 83 . An analysis of kidney findings at autopsy of 26 COVID-19 positive patients in Wuhan showed tubular injury and direct viral infiltration of the tubular epithelium 84, 85 . Data also suggests that renal dysfunction may be multifactorial due to cytokine storm, hemodynamic changes, direct viral toxicity, or thrombotic microangiopathy 86 . Renal deterioration has been associated with a 5.3-fold increased mortality in COVID-19 patients. Often these patients demonstrate radiographic evidence of kidney dysfunction, such as renal interstitial inflammation and edema on CT 87 . A recent published report detailed the case of an African American male patient who presented with acute kidney injury due to collapsing glomerulopathy in the context of a COVID-19 infection without any signs of respiratory disease, indicating that renal manifestations of COVID-19 are possible even in patients with otherwise mild symptoms 85 .

While research suggests that advanced age, organ failure, and elevated d-dimer levels are indicators of poor prognosis in COVID-19 patients, a recent study highlights kidney dysfunction as a potential risk factor for mortality, as well 13, 87 . A multi-center retrospective study of 193 COVID-19 patients (128 with non-severe disease, 65 severe) investigated the presence of kidney dysfunction and demonstrated that, on admission, 59% of patients had proteinuria, 44% had hematuria, 14% had elevated BUN, and 10% had elevated creatinine levels 87 . These lab derangements were found to be significantly worse in those J o u r n a l P r e -p r o o f with critical illness (including non-survivors), and 66% of the patients who developed an AKI (43/65) were considered to have severe disease 87 . Per Pei at el., 75.4% of patients with COVID-19 had an abnormal urine dipstick at initial presentation 88 . These findings have been reproduced by several other studies which have shown that development of an AKI is a common lab finding in COVID-19 and a feature of those with severe disease 5, 10, 43, [89] [90] [91] . Patients with elevated creatinine at admission were more likely to be admitted to the ICU 4,91-93 . Patients who survive COVID-19-related AKI have been shown to be at an increased risk of developing progressive CKD after the initial infection 86 . The risk CKD is associated with the severity of the AKI and the presence or absence of tubular damage 94 . These results suggest that early recognition of kidney dysfunction in patients with SARS-CoV-2 is important for disposition and monitoring for potential decompensation and to reduce the progression to chronic kidney impairment.

In addition to being a predictor of severe disease, Li et al. demonstrated that patients who developed an AKI had a 5.3-fold increased risk of mortality compared to those without kidney abnormalities, illustrating the importance of renal dysfunction as a negative prognostic indicator for survival 87 . Chen et al. also determined that 25% of non-survivors had developed an AKI during hospitalization 43 . One study noted that the kidney was the third most commonly damaged organ after the lungs and heart in those who died due to COVID-19 89 . A consecutive cohort study of 710 COVID-19 positive patients confirmed that markers of kidney dysfunction such as elevated BUN and creatinine were independent risk factors for in-hospital death even after adjusting for potential confounders 91 . Mortality for those who presented with evidence of renal failure on admission was 33.7% vs. 13.2% in those without kidney dysfunction 91 . Similarly, Pei et al. demonstrated that patients with renal involvement had higher overall mortality compared to those without (11.2% vs 1.2%) 88 . Patients with chronic kidney disease are particularly vulnerable to negative outcomes. A recent meta-analysis confirmed that those with preexisting renal dysfunction appeared to have significantly higher pneumonia-related mortality than those without underlying renal disease and are at increased risk for severe COVID-19 infection 95, 96 .

When comparing SARS-CoV-2 with SARS-CoV, AKI was a much less common finding (6%) during the 2003 outbreak of SARS, but it was recognized as a significant indicator of mortality (92% of SARS patients with AKI died) 92 . Similarly, renal dysfunction was also associated with increased risk of death in patients infected with H1N1 93 . Evidence of the prognostic implications of kidney injury in other serious respiratory viruses highlights the importance of recognizing dysfunction early in the disease course in order to improve morbidity and mortality. Early recognition and treatment of renal dysfunction may help to improve the prognosis of those infected with COVID-19.

Based on a study of 1099 confirmed COVID-19 cases in Wuhan, China, the most common symptoms included fever (43.8% of patients were febrile on admission, and 88.7% of patients became febrile during their hospital stay), cough (67.8%), and fatigue (38.1%). However, the study did note that 2 J o u r n a l P r e -p r o o f patients (0.2%) had rashes but did elaborate further 5 . There are several mentions in the literature of the dermatologic manifestations of SARS-CoV-2, but a predictable pattern has yet to emerge in the research.

Dermatologists have become increasingly involved in caring for COVID-19 patients due to shifting clinical responsibilities during the pandemic, thus sparking an interest in the possible cutaneous manifestations of SARS-CoV-2. Recalcati Several case reports have also described the potential skin manifestations of COVID-19. A cluster of eight children in the U.K. presented with features similar to atypical Kawasaki including the archetypal skin rash appearance 100 . Following this report, additional cases with similar presentation were observed across the globe. Henry et al. outlined the case of a 27-year-old female who presented with pruritic disseminated erythematous plaques without cough or fever. Two days later she tested positive for COVID-19 after the onset of chest pain and fever 101 . Another case report discussed a 28-year-old female who developed confluent "erythematous-yellowish" papules that progressed to pruritic, hardened plaques 13 days after testing positive for COVID-19 102 . Joob and Wiwanitkit detailed the case of a petechial eruption and thrombocytopenia initially thought to be Dengue fever, but ultimately proven to be COVID-19 after the development of respiratory symptoms 103 . Amatore et al. discussed a 39-year-old male who complained of fever and exhibited "erythematous and edematous non-pruritic annular fixed plaques involving the upper limbs, chest, neck, abdomen and palms, sparing the face and mucous membranes" without cough or dyspnea 104 

Dermatologists have been challenged with differentiating between infectious and allergic etiologies of rashes associated with COVID-19, since they are both clinically and histologically similar. Many of the J o u r n a l P r e -p r o o f medication combinations currently under investigation for the treatment of the virus may lead to drug eruptions 106 . In a study of 140 COVID-19 patients by Zhang et al., drug hypersensitivity (11.4%) and urticaria (1.4%) were the most prevalent cutaneous symptoms associated with the virus 16 . Jimenez-Cauhe et al. described a patient with "erythemato-purpuric, millimetric, coalescing macules, located in flexural regions" that developed 3 days into treatment with hydroxychloroquine and lopinavir/ritonavir 107 . It was unclear whether these lesions were a manifestation of SARS-CoV-2 or an adverse reaction to the medications; however, there are no additional reports of dermatological symptoms in patients treated with this combination therapy 107 . Another report described sterile pustules, similar to the typical findings of acute generalized exanthematous pustulosis (AGEP), as a cutaneous manifestation of COVID-19 108 . Although AGEP is classically associated with drugs, it is possible that COVID-19 can predispose certain patients to develop AGEP-like cutaneous eruptions as a late-onset manifestation of the infection.

In addition to potential drug hypersensitivity or direct viral infection of the skin, Manalo et al. hypothesized that underlying DIC and microthrombi may contribute to cutaneous symptoms 109 . The study described two cases of unilateral transient livedo reticularis in non-critically ill COVID-19 positive patients. Similarly, a retrospective study of 7 critically ill patients in Wuhan, China exhibited significant limb ischemia with plantar plaques and acral cyanosis as dermatologic manifestations of their underlying hypercoagulable state 110 .

While the cutaneous manifestations of COVID-19 can vary, early identification of unusual lesions in those without a known trigger is crucial to limiting the spread of COVID-19.

Recent studies have indicated that the SARS-CoV-2 is similar in taxonomy and sequence to the SARS-CoV virus 111 . The virus utilizes a spike protein S1 to attach to the host membrane by interacting with host ACE-2 receptor, which is found on neurons, endothelial cells, kidneys, lungs, and small intestine 112 . Upon entering the cell, it initiates an immune cascade which stimulates CD4 + T cells, and this sequence of events activates macrophages to produce IL-6, leading to a cytokine storm and eventual systemic destruction of tissues 113 . There are several neurological manifestations of the virus that are important to recognize and treat early.

The SARS-CoV-2 virus is known to cause severe respiratory distress through direct invasion into the lung parenchyma as evidenced by the destructive pattern seen on imaging of COVID-19 positive patients. However, some patients with evidence of significant lung damage and severe hypoxic do not develop J o u r n a l P r e -p r o o f tachypnea 114 . Scientists have hypothesized that there is an abnormal response of the peripheral afferent fibers in the lungs and airways that stimulate respiration 114 . Direct entry of the virus into brain tissue, notably the brainstem, may also result in the loss of involuntary control of breathing 115, 116 .

SARS-CoV-2 is believed to enter the nervous system via hematogenous spread, directly through the cribriform plate, or through retrograde neuronal synapses from the olfactory bulb and vagal afferents 111, 113, 117, 118 . Upon entering the nervous system, it can manifest as a viral encephalitis, cerebrovascular disease, or peripheral nerve symptoms 117,119,120 .

Various case reports summarized in Table 3 suggest that COVID-19 causes symptoms consistent with meningoencephalitis [121] [122] [123] [124] . Some COVID-19 positive patients presented with altered mental status and fever, and CSF studies showed elevated lymphocyte count but a negative viral biofire [121] [122] [123] [124] . Though these presentations could not be definitively linked to the virus due to the lack of CSF SARS-CoV-2 testing at the time, no other etiology for the viral meningoencephalitis was found in this COVID-19 positive cohort. A study conducted at the Beijing Ditan Hospital did confirm the presence of SARS-CoV-2 in the cerebrospinal fluid of patients with known COVID-19 and symptoms consistent with encephalitis by genome sequencing 125 . Evidence of infectious toxic encephalitis was also found when cerebral edema was identified during autopsy of COVID-19 patients 38 . A recently published report detailed the case of serious neurologic damage and mental abnormalities in a patient whose infection was confirmed by IgM and IgG antibodies in the CSF despite negative nasopharyngeal swabs. After the initial presentation of fatigue and headaches, the patient suddenly developed the inability to walk, uroclepsia, coprolalia, and delusions. His CSF studies were strongly positive for SARS-CoV-2 antibodies, and after weeks of antiviral and antipsychotic treatment, he was discharged with mild hand tremors and fatigue 126 .

A large retrospective study of 221 patients with COVID-19 at the Union hospital in Wuhan found that 5% of patients presented with acute ischemic stroke, one patient developed cerebral venous sinus thrombosis (CVST), and one had cerebral hemorrhage 127, 128 . Those with cerebrovascular disease were significantly older (71·6 ± 15·7 years vs 52·1 ± 15·3 years; p<0·05) and had cardiovascular risk factors. Lab evaluation of this cohort determined that they were more likely to have elevated CRP and d-dimer, lymphopenia, thrombocytopenia, and uremia [127] [128] [129] .

Cerebral hemorrhage is thought to be a consequence of the virus binding to ACE-2 receptors on endothelium, contributing to break down of the blood brain barrier 117, 120 . Ischemic changes and CVST are likely secondary to a hypercoagulable and pro-inflammatory state, further supported by elevation in CRP and d-dimer in these patients 117, 128, 129 . Numerous other studies summarized in Table 2 discuss  presentations of cerebrovascular disease in COVID-19 patients 120, 128, 129 .

While it is theorized in many of the aforementioned studies that patients who are COVID-19 positive are at increased risk for cerebral ischemia, research out of Piacenza, Italy noted decreased rates of admission for stroke. They reported only 6 admissions for CVA from February 21, 2020 to March 25, 2020 compared to their normal monthly average of approximately 51 cases 130 . The authors put forth a number of theories for these findings, such as thrombocytopenia or the potential neuroprotective role of IL-6. Research related to CVA incidence in the time of COVID is currently mixed, and further studies need to be conducted to corroborate these findings.

Since many studies have demonstrated that COVID-19 patients are at increased risk for encephalopathy and cerebrovascular disorders, it has been theorized that these clinical scenarios could lead to seizures [127] [128] [129] . However, a large multi-center retrospective study of 304 COVID-19 positive patients in China study evaluated seizure activity in a cohort of patients with no prior history of epilepsy 121 . Only two patients were identified as having seizure-like activity despite the presence of potentially predisposing hypoxia or electrolyte abnormalities in the majority of the cohort. Both patients were later found to have severe electrolyte abnormalities, and symptoms improved with correction 121 . A study of 111 COVID-19 patients within the New York academic hospital system investigated EEG abnormalities among infected patients. This study showed that the most frequent EEG finding was generalized slowing (57%) and epileptiform findings were observed in 30% and seizures in 7% (4% were non-convulsive seizures). The study also concluded that only a history of epilepsy and definite clinical seizures prior to EEG testing independently predicted epileptiform findings on EEG 131 .

Though most research efforts have been focused on identifying CNS dysfunction in SARS-CoV-2, some studies have discussed the effect on the peripheral nervous system. One case series reported on a patient with COVID-19-related Miller-Fisher syndrome and another with polyneuritis cranialis. The first patient developed characteristic features with external ophthalmoplegia, ataxia, and loss of tendon reflexes and recovered after being treated with IVIG 132 . The second had ageusia, areflexia, and abducens palsy consistent with polyneuritis cranialis, which spontaneously and rapidly improved 132 . A large retrospective study by Mao L et al. determined that 5% of patients had hypogeusia and another 5% had hyposmia 129 . Several Chinese studies indicated that up to 70% of patients complained of myalgias with increases in creatine kinase (CK) present in up to 33%, suggesting a possible SARS-CoV-2 viral myositis 2, 3, 28, 124, 133 . A recently published report details the case of acute transverse myelitis after a complicated SARS-CoV-2 infection. The patient developed hypotonia in both lower limbs with absent J o u r n a l P r e -p r o o f distal reflexes. An MRI with gadolinium contrast showed increased T2 signal between C7-T12 with an LP significant for an elevated IgG index and a positive RT-PCR for SARS-CoV-2. He recovered one week later after treatment with IVIG 134 .

With the rise of COVID-19 cases in the US, social distancing measures have continued significantly past their predicted duration, likely contributing to increased anxiety, depression, and loneliness. Prior epidemics have negatively impacted the psychological health of the population. A prospective study conducted during the 2003 SARS epidemic in Hong Kong demonstrated that stress, dysphoria, impaired sleep and concentration were much greater among infected individuals than controls, and 25% of the patients requested follow-up for the negative psychological effects of being infected 135 . A study examining psychiatric symptoms in SARS survivors one year later indicated that these patients experienced persistent distress with 64% scoring above the GHQ12 threshold for psychiatric morbidity 136 . Additionally, infected healthcare workers who survived showed significantly higher stress levels, more depression, and symptoms consistent with PTSD 136 . Based on this research, it is possible we will see similar patterns of anxiety, depression and other psychiatric symptoms in those currently affected by COVID-19.

The psychological impact of this pandemic is likely multifactorial, due in parts to self-isolation, fear of infection, uncertainty, financial woes, job insecurity, and pre-existing mental health conditions. A recent study out of China using online surveys determined that 16.5% of respondents exhibited moderate to severe depressive symptoms, and 28.8% reported severe anxiety 137 . Of these respondents, 75.2% attributed their increased anxiety to fear that they or their family members could contract COVID-19 137 . Misinformation and uncertainly can raise anxiety levels in both healthy individuals and those with preexisting psychiatric conditions 138 . Lunn et al. observed that the absence of effective disease treatment and the uncertainty regarding outcomes for those infected has led to mass panic and anxiety 139 . In addition, the rapid spread of misinformation and bias has induced fear, prejudice, and xenophobia 140,141 .

One of the major consequences of the pandemic is increased social isolation, a risk factor that is strongly associated with depression, self-harm, and suicide [142] [143] [144] . Older adults are especially vulnerable to the mental health ramifications of social isolation, particularly those in residential care 145 . Mental health experts have stressed the importance of research examining the rates of anxiety, depression, and other psychiatric symptoms to inform interventions during this public health crisis 142 . An analysis of emotional indicators on the Chinese social media platform Weibo during the height of their COVID-19 crisis demonstrated that anxiety and depression increased while positive emotional indicators (Oxford happiness) decreased 146 . The study also analyzed linguistic expression and determined that there was an increase in the use of the words "health" and "family" and a decrease in "leisure" and "friend", highlighting the rapidly evolving priorities in this population during the pandemic 146 .

Patients with pre-existing mental health conditions are both more vulnerable to the psychological impacts of the pandemic and at increased risk of infection, likely due to cognitive impairment, diminished efforts for personal protection, lack of awareness of their personal risk, and discrimination 147 . Patients with severe mental illness are also more vulnerable due to significantly higher rates of both homelessness and smoking 148 . Many patients have reported poor adherence to medication during this time, disruption of mental health services, and suspension of substance abuse treatment 149 . Lastly, the close proximity with which many homeless patients with mental illness live is a significant risk factor for the spread of the virus.

There is some emerging research that suggests a link between COVID-19 infection and severe psychiatric symptoms. A cross-sectional study of 112 patients with COVID-19 reported higher levels of somatization, depression, anxiety, phobias, sleep disturbances, and eating disorders in infected patients compared to the healthy population 150 . Case reports have detailed the psychiatric presentations of patients with SARS-CoV-2 both during their acute infections and post-clinical recovery. One such patient presented to the hospital with extreme anxiety, suicidal ideation, agitation, and hallucination 151 . A case series out of Spain examined viral involvement in new-onset psychiatric symptoms. They discussed several patients who presented to the hospital with psychosis and concomitant infection with SARS-CoV-2 without any known history of prior mental health disorders 152 . While neither of these reports was able to establish whether the patients' psychoses were primary or secondary (related to treatment or acute delirium), these findings suggest the need for additional research on the neuropsychiatric manifestations of COVID-19 infection. J o u r n a l P r e -p r o o f 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical Characteristics of Coronavirus Disease 2019 in China

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

COVID-19 and the clinical hematology laboratory

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Laboratory abnormalities in patients with COVID-2019 infection

Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection

Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State

Covid-19 in Critically Ill Patients in the Seattle Region -Case Series

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Hematologic parameters in patients with COVID-19 infection

Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Prominent changes in blood coagulation of patients with SARS-CoV-2 infection

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past

Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia

Hematological findings and complications of COVID-19

SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis

Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection

Cardiovascular complications in COVID-19

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

The role of concomitant cardiovascular diseases and cardiac biomarkers for predicting mortality in critical COVID-19 patients

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic

Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic

Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province

COVID-19 and Cardiac Arrhythmias

Bradycardia in Patients With COVID-19: A Calm Before the Storm? Cureus

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Takotsubo syndrome as a complication in a critically ill COVID-19 patient

SARS-CoV-2, a novel virus with an unusual cardiac feature: inverted takotsubo syndrome

Takotsubo Syndrome in the Setting of COVID-19

Typical takotsubo syndrome triggered by SARS-CoV-2 infection

Analysis of 92 deceased patients with COVID-19

Gastrointestinal and Liver Manifestations in Patients with COVID-19

Covid-19 and the digestive system

Can COVID-19 present unusual GI symptoms?

Gastrointestinal Presentation in COVID-19 in Indonesia: A Case Report

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series

Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study

Lung Base Findings of Coronavirus Disease (COVID-19) on Abdominal CT in Patients With Predominant Gastrointestinal Symptoms

COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis

Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis

Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms

A case of COVID-19 patient with the diarrhea as initial symptom and literature review

First Case of 2019 Novel Coronavirus in the United States

Atypical manifestations of COVID-19 in general practice: a case of gastrointestinal symptoms

Gastrointestinal symptoms associated with severity of coronavirus disease 2019 (COVID-19): a pooled analysis

Gastrointestinal Symptoms and COVID-19: Case-Control Study from the United States

Report: Paralytic Ileus: A Potential Extrapulmonary Manifestation of Severe COVID-19

The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients

Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission

Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples from the Hong Kong Cohort and Systematic Review and Meta-analysis

Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding

Fecal specimen diagnosis 2019 novel coronavirus-infected pneumonia

The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes

COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission

Digestive system involvement of novel coronavirus infection: prevention and control infection from a gastroenterology perspective

Fecal transmission in COVID-19: A potential shedding route

COVID-19: gastrointestinal symptoms and potential sources of 2019-nCoV transmission

Upper gastrointestinal bleeding in COVID-19 inpatients: Incidence and management in a multicenter experience from Northern Italy

Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection

COVID-19 and gastrointestinal endoscopies: current insights and emergent strategies

Determining Urgent/Emergent status of Gastrointestinal (GI) Endoscopic Procedures in an Ambulatory Care Setting during the Coronavirus Disease of 2019 (COVID-19) Pandemic: Additional Factors that need to be considered

Gastrointestinal endoscopy during the COVID-19 pandemic: an updated review of guidelines and statements from international and national societies

Chapter of Gastroenterologists professional guidance on risk mitigation for gastrointestinal endoscopy during COVID-19 pandemic in

Gastrointestinal endoscopy during COVID-19 pandemic

Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection [Internet]. Infectious Diseases (except HIV/AIDS)

Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade

Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China

Acute Kidney Injury Due to Collapsing Glomerulopathy Following COVID-19 Infection

Outbreak of chronic renal failure: will this be a delayed heritage of COVID-19?

Caution on Kidney Dysfunctions of COVID-19 Patients

Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia

Clinical characteristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center

Bulk and Single-Cell Transcriptomics Identify Tobacco-Use Disparity in Lung Gene Expression of ACE2, the Receptor of 2019-nCov

Kidney disease is associated with in-hospital death of patients with COVID-19

Acute renal impairment in coronavirus-associated severe acute respiratory syndrome

Acute kidney injury in critically ill patients with pandemic influenza A pneumonia 2009 in Korea: A multicenter study

Clinical cause of presumed acute tubular necrosis requiring renal replacement therapy and outcome of critically ill patients: post hoc analysis of a prospective 7-year cohort study

Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection

Pulmonary Infectious Mortality Among Patients With End-Stage Renal Disease

Cutaneous manifestations in COVID-19: a first perspective

Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome

Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients

Hyperinflammatory shock in children during COVID-19 pandemic

Urticarial eruption in COVID-19 infection

Cutaneous manifestations in COVID-19: a new contribution

COVID-19 can present with a rash and be mistaken for dengue

SARS-CoV-2 infection presenting as a febrile rash

Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection

Dermatology staff participate in fight against Covid-19 in China

Reply to "COVID-19 can present with a rash and be mistaken for Dengue": Petechial rash in a patient with COVID-19 infection

Late-onset AGEP -like skin pustular eruption following COVID -19: a possible association

A Dermatologic Manifestation of COVID-19: Transient Livedo Reticularis

Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms

Letter to the Editor Regarding the Viewpoint "Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanism

Lack of dyspnea in Covid-19 patients; another neurological conundrum?

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19

Nervous system involvement after infection with COVID-19 and other coronaviruses

Novel Coronavirus Disease (COVID-19) and Central Nervous System Complications: What Neurologist Need to Know

A New Symptom of COVID-19: Loss of Taste and Smell

Potential neurological symptoms of COVID-19

New onset acute symptomatic seizure and risk factors in coronavirus disease 2019: A retrospective multicenter study

Meningoencephalitis without respiratory failure in a young female patient with COVID-19 infection in Downtown Los Angeles

Concomitant neurological symptoms observed in a patient diagnosed with coronavirus disease 2019

Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China

Xiang: First case of 2019 novel coronavirus disease

Coronavirus disease 2019 associated with aggressive neurological and mental abnormalities confirmed based on cerebrospinal fluid antibodies: A case report

Response to Commentary on "The neuroinvasive potential of SARS-CoV-2 may play a role in the respiratory failure of COVID-19 patients

Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

The Baffling Case of Ischemic Stroke Disappearance from the Casualty Department in the COVID-19 Era

Continuous EEG findings in patients with COVID-19 infection admitted to a New York academic hospital system

Miller Fisher Syndrome and polyneuritis cranialis in COVID-19

COVID-19 and neuromuscular disorders

Acute Transverse Myelitis After SARS-CoV-2 Infection: A Rare Complicated Case of Rapid Onset Paraplegia in a Male Veteran&nbsp

Review; 2020

Stress and psychological impact on SARS patients during the outbreak

Stress and Psychological Distress among SARS Survivors 1 Year after the Outbreak

Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China

Public responses to the novel 2019 coronavirus (2019-nCoV) in Japan: Mental health consequences and target populations

COVID-19 PANDEMIA AND PUBLIC AND GLOBAL MENTAL HEALTH FROM THE PERSPECTIVE OF GLOBAL HEALTH SECURITY

Infodemiological study on COVID-19 epidemic and COVID-19 infodemic

Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science

Contribution of risk factors to excess mortality in isolated and lonely individuals: an analysis of data from the UK Biobank cohort study

Lonely young adults in modern Britain: findings from an epidemiological cohort study

COVID-19: the implications for suicide in older adults

The Impact of COVID-19 Epidemic Declaration on Psychological Consequences: A Study on Active Weibo Users

Patients with mental health disorders in the COVID-19 epidemic

Addressing the COVID-19 Pandemic in Populations With Serious Mental Illness

Impact of COVID-19-related stress and lockdown on mental health among people living with HIV in Argentina

Mental health status of patients with coronavirus disease 2019 in Changsha. Zhong Nan Da Xue Xue Bao Yi Xue Ban

COVID-19 Psychosis: A Potential New Neuropsychiatric Condition Triggered by Novel Coronavirus Infection and the Inflammatory Response?